Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled A Phase 1, Multicenter, Parallel-Design, Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment. The study aims to understand how LY3537031 is processed in the body of individuals with varying levels of kidney function, including those with renal impairment and end-stage renal disease (ESRD).
Intervention/Treatment: The study is testing LY3537031, a drug administered subcutaneously. It is designed to evaluate the drug’s pharmacokinetics and safety in both healthy participants and those with different degrees of renal impairment.
Study Design: This interventional study uses a non-randomized, parallel model with no masking. Its primary purpose is basic science, focusing on the drug’s behavior in the body.
Study Timeline: The study is not yet recruiting as of the last update on September 24, 2025. It was first submitted on September 3, 2025. Key completion dates are yet to be announced.
Market Implications: The study’s progress could influence Eli Lilly’s stock performance, as successful results may enhance investor confidence in the company’s pipeline. The study’s outcome could also impact the competitive landscape in treatments for renal impairment.
Closing Sentence: The study is ongoing, with further details available on the ClinicalTrials portal.